Lakefront Biotherapeutics (LKFT) Profit After Tax (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Profit After Tax data on file, last reported at $17.0 million in Q1 2026.

• Profit After Tax for Q1 2026 came in at $17.0 million, up 110.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $561.8 million (up 413.13% YoY), and the FY2025 annual result was $373.5 million, up 371.84% from the prior year.
• Profit After Tax declined to $17.0 million in Q1 2026 per LKFT's latest filing, from $910.5 million in the prior quarter.
• Over five years, Profit After Tax peaked at $910.5 million in Q4 2025 and troughed at -$539.1 million in Q3 2025.
• A 5-year average of $31.5 million and a median of $19.3 million in 2022 frame the typical range for Profit After Tax.
• On a YoY basis, Profit After Tax climbed as much as 3266.69% in 2025 and fell as far as 2104.51% in 2025.
• A 5-year view of Profit After Tax shows it stood at -$211.4 million in 2022, then jumped by 180.19% to $169.5 million in 2023, then plunged by 84.05% to $27.0 million in 2024, then soared by 3266.69% to $910.5 million in 2025, then slumped by 98.14% to $17.0 million in 2026.
• Business Quant data shows LKFT's Profit After Tax at $17.0 million in Q1 2026, $910.5 million in Q4 2025, and -$539.1 million in Q3 2025.